CAPTRUST Financial Advisors
EPZM

CAPTRUST Financial Advisors’s Epizyme, Inc EPZM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-521
Closed -$1K – 5289
2022
Q1 		$1K Buy
+521
New +$849 ﹤0.01% 4820
2021
Q3 		– Sell
-680
Closed -$6K – 4869
2021
Q2 		$6K Buy
680
+647
+1,961% +$5.46K ﹤0.01% 3817
2021
Q1 		$0 Buy
+33
New +$341 ﹤0.01% 4548
2019
Q3 		– Sell
-747
Closed -$9K – 2049
2019
Q2 		$9K Buy
+747
New +$9.61K ﹤0.01% 1541

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors's EPZM Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 521 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in EPZM in Q2 2019 and held it in 4 quarters. The position peaked at $9K in Q2 2019. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 521 Epizyme, Inc shares in Q2 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Epizyme, Inc in Q2 2019 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Epizyme, Inc position peaked at $9K in Q2 2019.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.